{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT06352073",
      "orgStudyIdInfo": {
        "id": "23-2625"
      },
      "secondaryIdInfos": [
        {
          "id": "R668-EE-2380",
          "type": "OTHER",
          "domain": "Regeneron"
        }
      ],
      "organization": {
        "fullName": "University of North Carolina, Chapel Hill",
        "class": "OTHER"
      },
      "briefTitle": "Dupilumab for Eosinophilic Esophagitis With Severe Strictures",
      "officialTitle": "Dupilumab for Eosinophilic Esophagitis With Severe Strictures (DESTRICT Study)",
      "acronym": "DESTRICT"
    },
    "statusModule": {
      "statusVerifiedDate": "2024-08",
      "overallStatus": "RECRUITING",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2024-05-09",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2025-11",
        "type": "ESTIMATED"
      },
      "completionDateStruct": {
        "date": "2026-04",
        "type": "ESTIMATED"
      },
      "studyFirstSubmitDate": "2024-04-01",
      "studyFirstSubmitQcDate": "2024-04-05",
      "studyFirstPostDateStruct": {
        "date": "2024-04-08",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2024-08-22",
      "lastUpdatePostDateStruct": {
        "date": "2024-08-26",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "University of North Carolina, Chapel Hill",
        "class": "OTHER"
      },
      "collaborators": [
        {
          "name": "Regeneron Pharmaceuticals",
          "class": "INDUSTRY"
        },
        {
          "name": "Sanofi",
          "class": "INDUSTRY"
        }
      ]
    },
    "conditionsModule": {
      "conditions": [
        "Eosinophilic Esophagitis",
        "EoE"
      ],
      "keywords": [
        "EoE",
        "Stricture",
        "dupilumab",
        "Eosinophilic Esophagitis"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "designInfo": {
        "allocation": "NA",
        "interventionModel": "SINGLE_GROUP",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "NONE"
        }
      },
      "enrollmentInfo": {
        "count": 30,
        "type": "ESTIMATED"
      }
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Histologic Response to Dupilumab",
          "description": "Proportion (percentage) of patients with histologic response, defined as \\<15 eosinophils per high-power field (eos/hpf), after 24 weeks of dupilumab 300mg weekly.",
          "timeFrame": "24 weeks"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Change in Minimum Esophageal Caliber",
          "description": "Change in minimum esophageal caliber (measured in millimeters (mm)) as measured using EndoFLIP (Endoluminal Functional Lumen Imaging Probe) from baseline to week 24.",
          "timeFrame": "24 weeks"
        },
        {
          "measure": "Decrease in Number of Dilations",
          "description": "Decrease in the total number of esophageal dilations (esophageal stretching) required throughout the study (which includes four endoscopies - screening, week 12, week 24, and week 52) compared to the number of dilations performed over the four endoscopies prior to study entry.",
          "timeFrame": "52 weeks"
        },
        {
          "measure": "Change in Endoscopic Severity",
          "description": "Change in endoscopic severity, measured using the EoE Endoscope Reference Score (EREFS), from baseline to week 24. The score ranges from 0-9, with higher scores indicating greater severity.",
          "timeFrame": "24 weeks"
        },
        {
          "measure": "Change in Histologic Severity",
          "description": "Change in histologic severity, measured using the EoE Histologic Scoring System (HSS), from baseline to week 24. The HSS score ranges from 0-1, with higher scores indicating greater severity. This study will compare both grade (most severe area) and stage (extent of involvement) parameters of the HSS.",
          "timeFrame": "24 weeks"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Requirements to be eligible for the study:\n\n* Age 16 and older.\n* Diagnosis of EoE (per 2018 AGREE consensus guidelines)\n* Currently active EoE (defined as \u226515 eos/hpf \\[eosinophils per high power field\\]) based on samples taken from the screening endoscopy.\n* Prior intolerance to or histologic non-response (defined as a peak esophageal eosinophil count of \u226515 eos/hpf) to proton pump inhibitors (PPI) and topical corticosteroids (tCS).\n* For PPI, this must be after 8 weeks or more of treatment of at least 40mg daily of any of the approved medications.\n* For tCS, this must be after 8 weeks or more of treatment of at least 2mg daily for budesonide or 1760 mcg daily for fluticasone).\n* One of the following specific EoE features: 1) a narrow esophagus where a standard adult endoscope would not fit or 2) 4 or more prior esophageal dilations (stretching procedures), with at least 2 dilations reported within one year.\n* Willing to follow certain lifestyle considerations during the study including:\n* No diet changes,\n* No changes in PPI medication dose,\n* No topical/swallowed (tCS) or systemic steroids for add-on EoE therapy,\n* Use highly effective birth control methods.\n* Weigh at least 40kg (about 89 pounds or more).\n\nReasons a participant could be excluded:\n\n* Other eosinophilic gastrointestinal (GI) disease including:\n\n  * Eosinophilic gastritis,\n  * Eosinophilic enteritis,\n  * Eosinophilic colitis,\n  * Hypereosinophilic syndrome.\n* Recent steroid use (systemic or swallowed/topical corticosteroid within 4 weeks prior to the screening endoscopy).\n* Recent use of dupilumab (Dupixent) (within 6 months of screening).\n* Prior allergic reaction to dupilumab or its components, or dupilumab intolerance.\n* Recent use of other biologic medications (within either 6 months or 5 half-lives, whichever is longer). Examples of biologic medications include:\n\n  * mepolizumab (Nucala),\n  * reslizumab (Cinqair, Cinqaero),\n  * benralizumab (Fasenra),\n  * cendakimab,\n  * tezepelumab (Tezspire),\n  * barzolvolimab, etc.\n* Prior esophageal resection (surgery to remove the esophagus).\n* Participants taking blood thinners (such as coumadin, warfarin, heparin, etc.) who are unable to stop taking them for a brief period prior to EGD (as required by normal clinical practice).\n* Recent vaccination with a live (attenuated) vaccine (within 4 weeks of screening). Live vaccines include:\n\n  * Chickenpox (varicella),\n  * FluMist and Intranasal influenza,\n  * Measles (rubeola),\n  * Mumps,\n  * Rubella,\n  * Oral polio,\n  * Oral typhoid,\n  * Smallpox (vaccinia),\n  * Yellow fever,\n  * Bacille Calmette-Guerin\n  * Rotavirus\n  * Combination vaccines of any of the above.\n* Study doctor's determination that it would not be medically safe to complete an EGD.\n* Inability to read or understand English.\n* Currently pregnant or breastfeeding.\n* Currently in screening or eligible for another study of dupilumab (Dupixent).",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "16 Years",
      "stdAges": [
        "CHILD",
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "centralContacts": [
        {
          "name": "Susan Moist, MPH",
          "role": "CONTACT",
          "phone": "919-918-5900",
          "email": "susan_moist@med.unc.edu"
        },
        {
          "name": "Lindsay Cortright, MA",
          "role": "CONTACT",
          "phone": "919-445-4911",
          "email": "lindsay_cortright@med.unc.edu"
        }
      ],
      "overallOfficials": [
        {
          "name": "Evan S Dellon, MD, MPH",
          "affiliation": "University of North Carolina, Chapel Hill",
          "role": "PRINCIPAL_INVESTIGATOR"
        }
      ],
      "locations": [
        {
          "facility": "University of North Carolina at Chapel Hill",
          "status": "RECRUITING",
          "city": "Chapel Hill",
          "state": "North Carolina",
          "zip": "27599",
          "country": "United States",
          "contacts": [
            {
              "name": "Julia Phillips",
              "role": "CONTACT",
              "phone": "919-843-4453",
              "email": "julia_phillips@med.unc.edu"
            }
          ],
          "geoPoint": {
            "lat": 35.9132,
            "lon": -79.05584
          }
        }
      ]
    }
  }
}